| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 3/6 |
Hypera S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R$4.70 |
| 52 Week High | R$8.35 |
| 52 Week Low | R$4.58 |
| Beta | 0.36 |
| 1 Month Change | -18.26% |
| 3 Month Change | -15.32% |
| 1 Year Change | -22.31% |
| 3 Year Change | -2.49% |
| 5 Year Change | -19.41% |
| Change since IPO | -5.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| HM6A | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.7% | 2.3% | 0.5% |
| 1Y | -22.3% | -28.6% | 1.3% |
Return vs Industry: HM6A exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: HM6A underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| HM6A volatility | |
|---|---|
| HM6A Average Weekly Movement | 8.3% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HM6A's share price has been volatile over the past 3 months.
Volatility Over Time: HM6A's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 10,301 | Breno Pires de Oliveira | www.hyperapharma.com.br |
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand.
Hypera S.A. Fundamentals Summary
| HM6A fundamental statistics | |
|---|---|
| Market cap | €3.29b |
| Earnings (TTM) | €297.75m |
| Revenue (TTM) | €1.43b |
11.0x
P/E Ratio2.3x
P/S RatioIs HM6A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HM6A income statement (TTM) | |
|---|---|
| Revenue | R$7.91b |
| Cost of Revenue | R$2.92b |
| Gross Profit | R$5.00b |
| Other Expenses | R$3.35b |
| Earnings | R$1.65b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | 2.60 |
| Gross Margin | 63.12% |
| Net Profit Margin | 20.83% |
| Debt/Equity Ratio | 86.5% |
How did HM6A perform over the long term?
See historical performance and comparison